SRP19 and the protein secretion machinery is a targetable vulnerability in cancers with APC loss
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2409677122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Xinqi Xi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology and Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia. Hauptthemen laut MEDLINE: Adenomatous Polyposis Coli Protein, Signal Recognition Particle, Adenomatous Polyposis Coli. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Federal Government | DHAC | National Health and Medical Research Council (NHMRC), Tour de Cure (TDC), VicGovAu | Victorian Cancer Agency (VCA).
Abstract (Originalsprache)
Loss of the tumor suppressor gene (TSG) Adenomatous Polyposis Coli ( APC ) is a hallmark event in colorectal cancers. Since it is not possible to directly target a TSG, no treatment options are available for these patients. Here, we identify SRP19 and the protein secretion machinery as a unique vulnerability in cancers with heterozygous APC loss. SRP19 is located 15 kb from APC and is almost always codeleted in these tumors. Heterozygous APC/SRP19 loss leads to lower levels of SRP19 mRNA and protein. Consequently, cells with APC/SRP19 loss are vulnerable to partial suppression of SRP19 . Moreover, we show that SRP19 is rate limiting for the formation of the Signal Recognition Particle, a complex that mediates ER-protein translocation, and thus, heterozygous SRP19 loss leads to less protein secretion and higher levels of ER-stress. As a result, low-dose arsenic trioxide induces ER-stress and inhibits proliferation in cultured cell lines and animal models. Our work identifies a strategy to treat cancers with APC deletion and provides a framework for identifying and translating vulnerabilities associated with loss of a TSG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology and Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
- Murdoch Children Research Institute, Parkville, VIC 3052, Australia.
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3052, Australia.
- Clinical Genomics, School of Translational Medicine, Monash University, Melbourne, VIC 3168, Australia.
- Department of Surgery, The University of Melbourne, Parkville, VIC 3050, Australia.
ORCID-Profile: Xinqi Xi, Ling Liu, Oliver Sieber, Max Cryle, Tu Nguyen-Dumont, Eva Segelov, Joseph Rosenbluh
Förderung
- Federal Government | DHAC | National Health and Medical Research Council (NHMRC)
- Tour de Cure (TDC)
- VicGovAu | Victorian Cancer Agency (VCA)
Zitieren
APA
Xi, X., Liu, L., Tuano, N., Tailhades, J., Mouradov, D., Steen, J., Sieber, O., Cryle, M., Nguyen-Dumont, T., Segelov, E., & Rosenbluh, J. (2025). SRP19 and the protein secretion machinery is a targetable vulnerability in cancers with APC loss. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2409677122
Vancouver
Xi X, Liu L, Tuano N, Tailhades J, Mouradov D, Steen J, et al. SRP19 and the protein secretion machinery is a targetable vulnerability in cancers with APC loss. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2409677122
BibTeX
@article{Xi2025,
author = {Xi, Xinqi and Liu, Ling and Tuano, Natasha and Tailhades, Julien and Mouradov, Dmitri and Steen, Jason and Sieber, Oliver and Cryle, Max and Nguyen-Dumont, Tu and Segelov, Eva and Rosenbluh, Joseph},
title = {SRP19 and the protein secretion machinery is a targetable vulnerability in cancers with APC loss},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2409677122}
}
EUVIMED